Global Neurodiagnostics Market Size study & Forecast, by Technology (Neuroimaging Technologies, In Vitro Diagnostics, Neuroinformatics) by End Use (Hospitals & Clinics) and Regional Forecasts 2022-2032

The Global Neurodiagnostics Market, valued at approximately USD 18.21 billion in 2024, is anticipated to grow at a steady CAGR of 3.80% between 2025 and 2035, reaching nearly USD 27.45 billion by the end of the forecast period. Neurodiagnostics, encompassing a wide array of technologies such as neuroimaging, in vitro diagnostics, and neuroinformatics, has evolved into an indispensable pillar of modern healthcare. It facilitates early detection, precise monitoring, and personalized treatment planning for a spectrum of neurological disorders, including Alzheimer’s disease, epilepsy, Parkinson’s disease, and multiple sclerosis. The rise in neurological disease prevalence, coupled with an aging global population and growing patient awareness, is amplifying the demand for advanced neurodiagnostic solutions. This heightened awareness, bolstered by continuous medical research and rapid technological progress, has positioned the market for sustained expansion over the next decade.

The increasing integration of AI and machine learning into neurodiagnostic platforms is redefining how clinicians interpret complex neurological data, enabling faster and more accurate diagnoses. Moreover, the surging demand for non-invasive and minimally invasive diagnostic procedures is pushing innovation in imaging modalities such as MRI, CT, PET, and EEG, as well as in advanced molecular and biomarker-based assays. According to recent healthcare studies, neurological disorders are among the top causes of disability worldwide, and their economic burden continues to escalate—driving both public and private sectors to invest heavily in cutting-edge diagnostic infrastructures. However, high equipment costs, limited access to advanced facilities in low- and middle-income countries, and the shortage of trained neuro-specialists may impede growth in certain regions, necessitating strategic collaborations to bridge these gaps.

North America currently holds a dominant share of the global neurodiagnostics market, driven by its robust healthcare infrastructure, high adoption rate of advanced imaging systems, and a strong presence of market-leading medical device companies. The United States, in particular, benefits from significant R&D funding, a large base of neurologists, and a high incidence of neurological conditions that necessitate regular diagnostic testing. Europe follows closely, with countries like Germany, France, and the UK leveraging well-established healthcare systems and government-backed research programs to promote innovation in neurodiagnostic solutions. The Asia Pacific region is expected to witness the fastest growth during the forecast period, supported by rising healthcare investments in China, India, and Japan, growing medical tourism, and the rapid expansion of specialized neurology centers. Meanwhile, Latin America and the Middle East & Africa are gradually emerging as promising markets, propelled by improving healthcare access, increased awareness campaigns, and the adoption of tele-neurology in underserved areas.

Major market players included in this report are:
• GE Healthcare
• Siemens Healthineers AG
• Canon Medical Systems Corporation
• Philips Healthcare
• Nihon Kohden Corporation
• Natus Medical Incorporated
• F. Hoffmann-La Roche Ltd
• Hitachi Medical Systems
• Medtronic plc
• Compumedics Limited
• Lifelines Neuro Company, LLC
• Advanced Brain Monitoring, Inc.
• Electrical Geodesics, Inc. (EGI)
• Masimo Corporation
• Micromed S.p.A.

Global Neurodiagnostics Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Technology:
• Neuroimaging Technologies
• In Vitro Diagnostics
• Neuroinformatics

By End Use:
• Hospitals & Clinics

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more